Storyline
Silicon Valley longevity body-reprogramming human trials
One page that accretes the verified record as the story develops. Every fact keeps its date and its sources.
1 DAYS
8 FACTS
1 EVENTS
1 SOURCES
FIRST ENTRY OCT 08
OCT 08 · Day 1
First human trial of Silicon Valley longevity body-reprogramming approaches
New Limit plans to begin its first human trials of a liver-cell reprogramming therapy in 2027.
New Limit raised $435 million in a Series C round led by Peter Thiel's Founders Fund.
Altos Labs hired Joan Mannick as head of product development.